{"id":"NCT00797797","sponsor":"Forest Laboratories","briefTitle":"Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","officialTitle":"A Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran When Added to Pregabalin in the Treatment of Fibromyalgia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2009-11","completion":"2010-01","firstPosted":"2008-11-25","resultsPosted":"2011-02-16","lastUpdate":"2011-02-16"},"enrollment":364,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"No Treatment Added","otherNames":["Lyrica (r)"]},{"type":"DRUG","name":"Milnacipran Added","otherNames":[]}],"arms":[{"label":"Milnacipran Added","type":"EXPERIMENTAL"},{"label":"No Treatment Added","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety, tolerability, and efficacy of milnacipran when taken with another drug called pregabalin in people with fibromyalgia.","primaryOutcome":{"measure":"Patient Global Impression of Change (PGIC) Responder Rate at End of Study","timeFrame":"End of Randomized treatment period (11 weeks)","effectByArm":[{"arm":"No Treatment Added","deltaMin":36,"sd":null},{"arm":"Milnacipran Added","deltaMin":83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":60,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":178},"commonTop":["Nausea","Weight Increased","Fatigue","Oedema peripheral","Headache"]}}